Edition:
United States

Mesoblast Ltd (MSB.AX)

MSB.AX on Australia Stock Exchange

1.22AUD
2 Dec 2016
Change (% chg)

$0.03 (+2.52%)
Prev Close
$1.19
Open
$1.20
Day's High
$1.25
Day's Low
$1.20
Volume
469,255
Avg. Vol
816,588
52-wk High
$3.03
52-wk Low
$1.01

Select another date:

Mon, Nov 14 2016

BRIEF-Mesoblast qtrly loss per share 5.24 cents

* Mesoblast provides corporate update and financial results for the first quarter ended September 30, 2016 Source text for Eikon: Further company coverage:

BRIEF-Mesoblast names Bill Burns as vice chairman

* Mesoblast appoints Bill Burns, former chief executive of Roche Pharmaceuticals, as vice chairman Source text for Eikon: Further company coverage:

BRIEF-Mesoblast reports Q4 earnings per share $0.1278

* Mesoblast reports financial results and operational highlights for the three months and for the year ended 30 june 2016

BRIEF-Mesoblast intends to enter into strategic partnership advancing phase 3 development of allogeneic MPCS for biologic Refractory RA

* Phase 2 trial of mesoblast cell therapy shows dose-related clinical benefit in patients with biologic refractory rheumatoid arthritis

Mesoblast cell treatment shows promise in rheumatoid arthritis : study

Mesoblast Ltd on Monday said its experimental stem-cell treatment led to significant improvements of symptoms and disease activity in patients whose rheumatoid arthritis had stopped being helped by widely used biotech medicines, according to data from a mid-stage trial.

Mesoblast cell treatment shows promise in rheumatoid arthritis -study

Aug 8 Mesoblast Ltd on Monday said its experimental stem-cell treatment led to significant improvements of symptoms and disease activity in patients whose rheumatoid arthritis had stopped being helped by widely used biotech medicines, according to data from a mid-stage trial.

BRIEF-Mesoblast provides update on heart failure trial and funding of clinical operations

* Mesoblast provides update on heart failure trial and funding of clinical operations Source text for Eikon: Further company coverage: )

UPDATE 1-Mesoblast shares slump to 2009 low as Teva ends partnership

* Mesoblast shares plummet 42 pct to lows not seen since 2009

Mesoblast regains full rights to stem cell heart failure treatment

Mesoblast Ltd on Monday said it had regained full rights to its experimental stem cell therapy for advanced chronic heart failure, which is currently in late stage testing, from Teva Pharmaceutical Industries.

Mesoblast regains full rights to stem cell heart failure treatment

Mesoblast Ltd on Monday said it had regained full rights to its experimental stem cell therapy for advanced chronic heart failure, which is currently in late stage testing, from Teva Pharmaceutical Industries.

Select another date: